natgillin/translations-raw huggingface dataset:
An Fc-containing molecule having decreased affinity for FcY receptors as compared to a wildtype Fc, comprising an antibody Fc domain based on an IgG2 constant region, wherein amino acid residues 233, 234, 235, 237, and 238 defined by the EU numbering system, comprise a sequence selected from PAAAP, PAAAS, and SAAAS and further comprising mutations H268A or H268Q, V309L, A330S and P331S as defined by the EU numbering system. 
Molekula koja sadrži Fc prema zahtjevu 1, koja ima smanjen afinitet za Fcy receptore u usporedbi sa Fc divljeg tipa, obuhvaćajući Fc domenu antitijela baziranu na IgG2 konstantnoj regiji, gdje aminokiselinski ostaci 233, 234, 235, 237, 1 238 definirani EU sistemom numeracije, sadrže sekvencu izabranu iz PAAAP, PAAAS i SAAAS 1 dalje obuhvaćajući mutacije H268A ili H268Q, V309L, A330S i P3315 kao što je definirano EU sistemom numeracije.
Composition according to any one of claims 1 to 6, wherein the sphingosine 1-phosphate receptor agonist is adapted for oral administration. 
Sastav za uporabu prema zahtjevu 1 ili 2, naznačen time, da je sastav prilagođen za oralno davanje.
is a cholinesterase inhibitor. 
(li) je inhibitor kolinesteraze.
granulating the raw materials from step (1) using a dry granulation process, wherein the apixaban particles have a D90 less than 89 µm as measured by laser light scattering; 
granulacije sirovih materijala iz koraka (1) primjenom procesa suhe granulacije, pri čemu čestice apiksabana imaju D90 manji od 50 µm mjereno pomoću rasipanja laserske svjetlosti;
rapidly lowering the pH of the reaction mixture to a pH of less than 2 by addition of nitric acid; wherein the isolated monomeric platinum (IV) complex has a formula of II or IV: 
(iv) brzo snižavanje pH reakcijske smjese na pH od manje od 2 dodavanjem dušične kiseline; pri čemu izolirani monomerni kompleks pina (IV) ima formulu II ili IV:
The method of claim 1, wherein the compound of Formula Ib is selected from the group consisting of: 
Spoj prema zahtjevu 1, naznačen time da ima strukturu odabranu iz skupine koja sadrži: * N=>
The pharmaceutical dosage form according to claim 2, wherein the relative molar content of the ethyl acrylate within the nonionic acrylic polymer is greater than the relative molar content of the methyl methacrylate within the nonionic acrylic polymer. 
Farmaceutski oblik doziranja prema zahtjevu 2, naznačen time što je relativni molarni sadržaj etil akrilata unutar neionskog akrilnog polimera veći od relativnog molarnog udjela metil metakrilata unutar neionskog akrilnog polimera.
A method of treating a patient suffering from a psychosis, comprising administering Compound (I) weekly in a single oral dose corresponding to between 20 mg/week and 50 mg/week calculated as the free base of Compound (I), wherein Compound (I) is 
HR P20181684 T1 (D prema zahtjevu 1, 2 ili 3 za uporabu prema zahtjevu 1, pri čemu se Spoj (I) primjenjuje jednom tjedno u dozi, računato kao slobodna baza Spoja (1), od oko 30 mg/dozi.
Further, the stability of the foam is higher when prepared using the sugar replacer, as illustrated by the spiral depth measured after 12 seconds. 
Nadalje, stabilnost pjene je veća ako se pripravlja sa zamjenom za šećer, kao što se vidi iz vrijednosti spiralne dubine nakon 12 sekundi.
It also shows the great interest in fatty acid esters as an ingredient in the pain formulations. 
Oni također pokazuju veliko zanimanje za estere masnih kiselina kao sastojka u formulacijama premaza.
Use of a compound according to any one of claims 1-13, or a pharmaceutically acceptable salt or an isomer thereof in the preparation of a medicament for treating and/or preventing kidney injury and/or cardiovascular disease including hypertension, heart failure, myocardial infarction, angina pectoris, cardiac hypertrophy, myocarditis, cardiovascular fibrosis, baroceptor dysfunction, excess fluid and arhythmia, or endocrine disease, including primary/secondary aldosteronism, Addison's disease, Cushing's syndrome and Bartter's syndrome. 
Spoj prema bilo kojem od zahtjeva 1-15, ili njegova farmaceutski prihvatljiva sol za uporabu u liječenju i/ili prevenciji ozljede bubrega i/ili kardiovaskularne bolesti uključujući hipertenziju, zatajenje srca, miokardijalni infarkt, anginu pectoris, srčanu hipertrofiju, miokarditis, kardiovaskularnu fibrozu, baroceptorsku disfunkciju, višak fluida 1 aritmiju, ili endokrine bolesti, uključujući primarni/sekundarni aldosteronizam, Addisonovu bolest, Cushingov sindrom i Bartterov sindrom.
Agents with a2 adrenergic receptor agonist activity may be selected from phenylpropanolamine, propylhexadrine, amphetamine, dextroamphetamine, ephedrine, epinine (deoxyepinephrine), ethylnorepinephrine, levarterenol (L-Norepinephrine), lofexidine, methamphetamine, a-methylnorepinephrine, methylphenidate, mivazerol, moxonidine, norepinephrine, norphenylephrine, pemoline, and tizanidine. 
Agonist za uporabu u skladu sa zahtjevom 3, naznačen time što je sredstvo s aktivnošću agonista alfa 2 adrenergijskog receptora odabrano od fenilpropanolamina, propilheksedrina, amfetamina, dekstroamfetamina, efedrina, -epinina, < etilnorepinefrina, = levarterenola, lofeksidina, metamfetamina, alfa-metilnorepinefrina, metilfenidata, mivazerola, moksonidina, norepinefrina, norfenilefrina, pemolina, tizanidina i njihovih kombinacija.
A pharmaceutical composition comprising a pharmaceutically acceptable carrier and the compound of any one of claims 1-5, or a pharmaceutically acceptable salt thereof. 
Farmaceutski sastav, naznačen time, da obuhvaća farmaceutski prihvatljiv nosač 1 spoj prema bilo kojem od zahtjeva 1 - 5, ili njegovu farmaceutski prihvatljivu sol.
Heat to 70° C. and thermostatically maintain the temperature. 
Zagrijavati do 70%C i termostatički održavati temperaturu.
The compound of Paragraph 1, selected form the group consisting of 
Spoj prema zahtjevu 1, izabran iz skupine koju čine:
The system of claim 1, wherein the at least one marking includes an alpha-numeric character, and the processor is configured to decode the alpha-numeric character via optical character recognition (OCR). 
Sustav prema patentnom zahtjevu 1, naznačen time, da barem jedna oznaka uključuje alfanumerički znak i procesor je konfiguriran tako da dekodira taj alfanumerički znak putem optičkog raspoznavanja znakova (OCR - Optical character recognition).
The rFSH may preferably include a2,6-sialylation in an amount which is from 25 to 50% of the total sialylation, for example from 30 to 50% of the total sialylation, for example from 31 to 38%, for example around 35% of the total sialylation. 
Proizvod prema patentnom zahtjevu 7, naznačen time da 1% do 50% ukupne sijalizacije je 02, 6- sijalizacija, a 50% do 99% ukupne sijalizacije je &2.3- sijalizacija.
TDOA: Time Difference Of Arrival NLOS: Non Line Of Sight According to a first aspect, the invention relates to a method for hotspot detection based on erroneous user location data, the method comprising: computing the ratio of the local user density within a first distance zone of the user density map towards a hotspot center point candidate to the local user density within a second distance zone of the user density map towards the same hotspot center point candidate and, if this ratio exceeds a specific threshold, assigning particular candidate points of the user density map within a certain distance to the hotspot center point candidate to a hotspot if the ratio of their user density to that one of the second distance zone exceeds the previously mentioned threshold, the hotspot representing a concentrated conglomeration of users of the mobile communication network; and detecting a center point of the hotspot based on the particular candidate points assigned to the hotspot. 
Postupak (100) za detekciju vruće točke na osnovi pogrešnih podataka o lokaciji korisnika, naznačen time što se postupak sastoji u: izračunavanju (102) omjera između gustoće lokalnih korisnika unutar zone prve udaljenosti na karti gustoće korisnika prema mogućoj središnjoj točki vruće točke i gustoće lokalnih korisnika unutar zone druge udaljenosti na karti gustoće korisnika prema istoj mogućoj središnjoj točki vruće točke i, ako taj omjer pređe prag, pridruživanju (103) određenih mogućih točkaka na karti gustoće korisnika unutar određene udaljenosti domoguće središnje točke vruće točke vrućoj točki ako omjer između njihove gustoće korisnika i one zone druge udaljenosti pređe prag, gdje vruća točka predstavlja koncentrirano nagomilavanje korisnika mobilne komunikacijske mreže; i detekciji (104) središnje točke vruće točke na osnovi određenih mogućih točaka pridruženih vrućoj točki.
Embodiment F. A compound of Embodiment B wherein R2 is pyridinyl, pyrimidinyl, oxazolyl or thiazolyl, each optionally substituted with up to 3 substituents independently selected from the group consisting of halogen and C1-C4 alkyl. 
R* je piridinil, pirimidinil, oksazolil ili tiazolil, pri čemu je svaki izborno supstituiran sa do 3 supstituenta nezavisno izabrana iz grupe koju čine halogen i C,-Ca alkil.
The apparatus of claim 1, being a twin belt caster (10) having two said endless belts (12, 14) made of said aluminum alloy. 
Uređaj prema zahtjevu 1, naznačen time da je uređaj za lijevanje s dvostrukim remenom (10) koji ima dva navedena beskonačna remena (12, 14) napravljena od navedene aluminijske legure.
A DPP-IV inhibitor according to any one of claims 12 to 16 wherein the DPP-IV inhibitor is MK-0431: 
Pripravak u skladu sa zahtjevom 1, naznačen time, da DPP-IV inhibitor je inhibitor humanog DPP-IV.
These non digestible, insoluble fibres also show some health promoting effects in, for instance, the prevention of constipation and the decrease of glucose levels in the blood of people with diabetes. 
Ta neprobavljiva, netopljiva vlakna iskazuju i neke učinke povoljne za zdravlje, na primjer, sprječavaju zatvor i snizuju razine glukoze u krvi osoba s dijabetesom.
R25A and R29A are independently selected from the group consisting of hydrogen, an optionally substituted C1-24 alkyl and an optionally substituted aryl; 
Ri R** su neovisno odabrani iz skupine koja sadrži vodik, po izboru supstituiran C,.», alkil i po izboru supstituiran aril;
The pharmaceutical composition of claim 3, characterized in that the total weight of the drug impurities is not more than 0.5 percent of the weight of the compound selected from the group consisting of imiquimod, sotirimod and resiquimod. 
Farmaceutski pripravak iz patentnog zahtjeva 2, naznačen time, da ukupna težina nečistoća u lijeku nije veća od 0,5 posto težinskog udjela spoja imikvimoda.
The oral dosage form of claim 3 or 4 wherein the crosslinked cation exchange polymer is represented by the general structure of Formula 40A: wherein m is in the range of from about 85 to about 93 mol% n is in the range of from about 1 to about 10 mol% and p is in the range of from about 1 to about 10 mol%, calculated based on the ratios of monomers added to the polymerization mixture; and the composition comprises 15 wt.% to 35 wt.% sorbitol, 10 wt.% to 25 wt.% water, and the remainder crosslinked cation exchange polymer, with the weight percents based on the total weight of sorbitol water and polymer. 
Fognula HA * p pri čemu m je u rasponu od oko 85 do oko 93 mol %, n je u rasponu od oko 1 do oko 10 mol % i p je u rasponu od oko 1 do oko 10 mol %, izračunato na temelju omjera monomera dodanih u polimerizacijsku smjesu; i pripravak sadrži 15 mas.% do 35 mas.% sorbitola, 10 mas. % do 25 mas. % vode, i ostatak je umreženi polimer za kationsku izmjenu, gdje su maseni postotci u odnosu na ukupnu masu sorbitola, vode i polimera.
The process of claim 1, wherein the soluble and/or water swellable coating material particles are hydrophilic polymer particles comprising a polymer selected from the group consisting of hydroxypropylmethylcellulose, hydroxypropylcellulose, poly-(ethylene oxide), polymethacrylates, lactose and combinations thereof. The process of claim 1, wherein the substantially water insoluble polymer particles comprise a polymer selected from the group consisting of polyethylene, polypropylene, polytetrafluoroethylene, carnauba wax, castor wax, polyamide wax, and combinations thereof. 
Postupak sukladno zahtjevu 1, naznačeno time, da su čestice materijala za prevlačenje čestice topive ili koje bubre u vodi hidrofile čestice i sadrže polimer i/ili spoj izabran iz skupine hidroksipropilmetilceluloze, hidroksipropilceluloze, poli-(etilen oksid), polimetakrilates, laktoze I ostalih sličnih kombinacija, i prema kojem se izrazito u vodi netopive polimerične čestice sadrže polimer izabran iz skupine polietilena, polipropilena, politetrafluoroetilena, karnauba voska, ricinusnog voska, poliamidni voska i ostalih sličnih kombinacija.
wherein RN is a substituted or unsubstituted hydrocarbyl group; wherein RL is a linker moiety, RB is a backbone moiety, and T is a template group which attaches each of the four chelating hydroxypyridinone moieties by their linking groups, 
pri čemu Ry je supstituirana ili nesupstituirana hidrokarbilna skupina; pri čemu R, je vezna skupina, Rg je dio okosnice, i T je skupina predloška koja povezuje svaku od četiri kelatizirajuće hidroksipiridinonske skupine s njihovim vezujućim skupinama, -
Additional ˜10 mL of ethyl acetate is added with sonication, as needed, to break up the precipitate. 
Doda se još -10 ml etil-acetata uz sonificiranje, po potrebi, kako bi se raščinilo talog.
The compound of claim 1, wherein Cy1 is selected from substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl. 
Cy1 je odabrano od supstituiranog ili nesupstituiranog arila i supstituiranog ili nesupstituiranog heteroarila;
The process of claim 1 or claim 2, further comprising operating the first reaction stage (14) at a temperature and pressure to hydrocrack the resid at an overall resid conversion of at least 60 wt.%. The process of claim 6, wherein the overall resid conversion is of at least 95 wt.%. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time, da nadalje obuhvaća djelovanje prvog reakcijskog stupnja (14) na temperaturi i tlaku za hidrokrekiranje ostatka uz ukupnu konverziju ostatka od najmanje 60 % težinskog udjela.
The formulation of claim 12, wherein the adjuvant is aluminum phosphate. 
Formulacija u skladu s patentnim zahtjevom 22, naznačena time što formulacija dodatno sadrži adjuvans, te što je adjuvans aluminijev fosfat.
The compound according to claim 7 wherein the disease, disorder or condition is anxiety disorders, such as panic disorder with or without agoraphobia, agoraphobia without history of panic disorder, animal and other phobias, including social phobias, obsessive-compulsive disorder, and generalized or substance-induced anxiety disorder. 
Spoj u skladu sa zahtjevom 7, naznačen time, što je bolest, poremećaj ili stanje depresija, kao što je panični poremećaj sa ili bez agorafobije, agorafobija bez povijesti paničnog poremećaja, strah od životinja i druge fobije, društvena fobija, opsesivno-kompulzivni poremećaj i opći ili posebni poremećaj uslijed depresije. t>&
Animals were euthanized on day 75 after the start of the protocol with pentobarbital i.v. 
Životinje su eutanazirane nakon 75 dana od početka protokola s pentobarbitalom i.v.
The pharmaceutical combination for use of any of the preceding claims, wherein the patient to be treated has a glucose excursion of at least 2 mmol/L, at least 3 mmol/L, at least 4 mmol/L or at least 5 mmol/L, wherein the glucose excursion is the difference of the 2 hours postprandial plasma glucose concentration and plasma glucose concentration 30 minutes prior to a meal test. 
Farmaceutska kombinacija za uporabu prema bilo kojem od prethodnih zahtjeva, naznačena time da pacijent koji se treba liječiti ima ekskurziju glukoze od barem 2 mmol/L, barem 3 mmol/L, barem 4 mmol/L ili barem 5 mmol/L, pri čemu ekskurzija glukoze je razlika koncentracije glukoze u plazmi 2 sata poslije jela i koncentracije glukoze u plazmi 30 minuta prije testa s obrokom.
The compound for use of claim 1, wherein the disease or disorder is multiple myeloma. 
Spoj ili sastav za uporabu prema zahtjevu 3, naznačen time, da bolest ili poremećaj je rak jetre.
The method of claim 23, in which rearranging the codons comprises the step of randomly selecting and exchanging pairs of codons encoding the same amino acid and determining whether codon pair bias is reduced by the exchange. The method of claim 24, wherein 
Postupak prema zahtjevu 23., naznačen time što preraspodjela kodona obuhvaća korak slučajnog odabira i izmjene parova kodona koji kodiraju istu aminokiselinu i određivanje je li pristranost para kodona smanjena preraspodjelom.
a light chain variable domain having a sequence with at least 90% identity to SEQ ID NO: 485 and a heavy chain variable domain having a sequence with at least 90% identity to SEQ ID NO:483; (ii) 
varijabilne domene lakog lanca koja ima slijed s najmanje 90% podudaranja sa SEQ ID NO: 485 i varijabilne domene teškog lanca koja ima slijed s najmanje 90% podudaranja sa SEQ ID NO: 483;
Utility of compounds of the disclosure as screening agents 
Datum objave europske prijave patenta:
The organic solvent was evaporated and pH adjusted to 4. 
Organsko otapalo se otpari i pH prilagodi na 4.
According to another preferred embodiment of the process according to the present invention, the hydrophobised ground calcium carbonate and/or the hydrophobised precipitated calcium carbonate obtained in step d) is used in powder form and/or in the form of granules or in the form of slurry. 
Postupak prema bilo kojem od prethodnih zahtjeva, naznačen time da se hidrofobirani prirodni kalcijev karbonat i/ili hidrofobirani taložni kalcijev karbonat koji je dobiven u koraku d) koristi u praškastom obliku i/ili u obliku granula ili u obliku suspenzije. HR P20160787 T1
In some embodiments according to any of the methods described above in this section, wherein the composition comprising nanoparticles comprising a taxane and albumin is administered parenterally. 
Pripravak ili kombinacija za uporabu prema bilo kojem od zahtjeva 1-9, gdje se pripravak koji sadrži nanočestice s taksanom i albuminom primjenjuje parenteralno, poželjno intravenski, intraarterijski, intrahepatalno ili intraportalno.
A compound of the formula I or a pharmaceutically acceptable salt thereof wherein 
Spoj s formulom I ili njegova farmaceutski prihvatljiva sol [image] pri čemu
The present invention relates to 4-(2-phenylsulfanyl-phenyl)-piperidine derivatives which are serotonin reuptake inhibitors and as such effective in the treatment of for example depression and anxiety. 
Ovaj izum se odnosi na derivate 4-(2-fenilsulfaml-fenil)-piperidina koji su inhibitori ponovne pohrane serotonina i kao takvi učinkoviti u liječenju na primjer depresije i tjeskobe.
The present invention is directed to compounds of the formula I: 
PATENTNI ZAHTJEVI 5 1. Spoj formule I: gdje:
The mixture was transferred to a fluidization rotogranulator (Glatt GPCG1), and a mixture of a solution of 2 g of xanthane gum in 250 ml of ion-exchanged water and 50 g of 35% dimethyl polysiloxane and a mixture of further 60 g of 35% dimethyl polysiloxane and 1000 ml of ion-exchanged water were sprayed onto it. 
Smjesa je prenesena u fluidizacijski rotacijski granulator (Glatt GPCGI1), pa je na nju raspršena smjesa otopine 2 g ksantanske gume u 250 ml ionsko-izmjenjivačke vode i 50 g 35% dimetil polisiloksana i dalje smjesa 60 g 35% dimetil polisiloksana i 1000 ml ionsko-izmjenjivačke vode.
Figure 5b shows that the design engraved in the plate has even here been transferred to the ink patch; the latter shows a 3-dimensional effect and a seems to move when the print is looked at from different angles. 
Slika 5b prikazuje kako je uzorak ugraviran u ploču 1 ovdje prenesen na otisak tinte; potonju odlikuje 3-dimenzionalni učinak, a kada se otisak gleda iz različitih kuteva čini se kako se kreće.
The solid form of claim 1, having a monoclinic crystal system, a P21/c centrosymmetric space group. 
koji ima monoklinski kristalni sustav, P21 / c centrosimetričnu prostornu skupinu i sljedeće parametre jediničnih stanica:
and R32 are independently hydrogen substituted hydrocarbyl, or hydrocarbyl; 
R22 1 R32 su nezavisno vodik supstituiran hidrokarbil ili hidrokarbil;
The combined organic layers are washed with water (1x30 mL) followed by brine solution (1x20 mL) and dried over anhydrous Na2SO4. 
Pomiješane organske slojeve ispere se vodom (1 x 30 ml) i slanom otopinom (1 x 20 ml), te osuši preko bezvodnog Na,SOa.
an antibody comprising a heavy chain variable region which comprises CDR1 comprising the amino acid sequence of SEQ ID NO: 1, CDR2 comprising the amino acid sequence of SEQ ID NO: 2, and CDR3 comprising the amino acid sequence of SEQ ID NO: 3, and comprising a light chain variable region which comprises CDR1 comprising the amino acid sequence of SEQ ID NO: 5, CDR2 comprising the amino acid sequence of SEQ ID NO: 6, and CDR3 comprising the amino acid sequence of SEQ ID NO: 7; 
PATENTNI ZAHTJEVI Anti-NR10 protutijelo, naznačeno time, da je to bilo koje od sljedećeg: (1) protutijelo koje sadržava varijabilne regije teških lanaca sa sekvencama CDRI od SEQ ID NO: 9, CDR2 od SEQ ID NO: 197 i CDR3 od SEQ ID NO: 184 (H30, H44) i varijabilnu regiju lakog lanca koja sadržava CDR1 od SEQ ID NO: 202, CDR2 od SEQ ID NO: 170 i CDR3 od SEQ ID NO: 193 (L17);
The composition of claim 1, wherein the composition is administered to an animal at a dosage range from about 105 pfu to about 109 pfu. 
Sastav prema bilo kojem od zahtjeva 1 do 6, naznačen time, da se sastav primjenjuje na životinji u doznom rasponu od 10? pfu do 10* pfu.
The Fc-containing molecule of embodiment 1, wherein the domain is capable of specifically binding FcRn. 
Molekula koja sadrži Fc iz patentnog zahtjeva 1, gdje je domena sposobna specifično vezati FcRn.
The aqueous layer is separated and carefully acidified with 1 N HCl. 
Vodeni sloj se odvoji, te pažljivo zakiseli s 1 N HCI.
Method for manufacturing a moulded fibre packaging in particular a food package, more particular an egg package, comprising, 
Metoda za proizvodnju oblikovanih pakiranja od vlakana (1), posebno pakiranja za hranu, još posebnije pakiranja za jaja, koja uključuje
The composition for the use according to any one of claims 1 to 4, wherein the anti-RSV immune response inducing composition that was administered to the female and the anti-RSV immune response inducing composition administered to the infant are the same. 
Pripravak namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 1 do 4, naznačen time što su pripravak koji izaziva imunosni odgovor protiv RSV kojeg se primjenjuje na ženi i pripravak koji izaziva imunosni odgovor protiv RSV kojeg se primjenjuje na dojenčetu isti.
The method of claim 1, wherein the intravaginal ring comprises: the progesterone, a dimethylpolysiloxane elastomer, and a pharmaceutically acceptable oil, in a ratio of about 4:15:1, respectively, wherein the progesterone is homogeneously dispersed in the elastomer, and wherein the progesterone is released from the monolithic intravaginal ring for up to about 18 days after administration to the patient. 
Monolitni intravaginalni prsten u skladu s patentnim zahtjevom 1, naznačen time, da je polisiloksan elastomer dimetilpolisiloksan elastomer, a omjer progesterona i elastomera iznosi 1: 1 do 1: 10, progesteron je homogeno raspršen u elastomeru, omjer progesterona i ugljikovodika ili glicerolnih estera masnih kiselina iznosi 1: 0,1 do 1: 100 i pri čemu se progesteron otpušta iz monolitnog intravaginalnog prstena do 18 dana nakon primjene na pacijentu.